Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment: an Ancillary Study of IDEA France Study

NCT03422601 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT03422601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment: an Ancillary Study of IDEA France Study
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Observational
Overall status
Unknown status
Start date
July 13, 2017
Completion date
July 15, 2019
Enrollment
1,122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, stage iii colon cancer